The earnings call showcased strong growth in Fanapt revenue and expansion of the sales force, alongside successful regulatory progress with Bysanti. However, the company faces challenges with increased net losses, declining revenues for HETLIOZ and PONVORY, and significantly increased operating expenses.

Company Guidance -

Q3 2025

During the Q2 2025 earnings call for Vanda Pharmaceuticals, significant guidance was provided concerning the company's financial and commercial progress. The revenue from the company's three commercial products, Fanapt, HETLIOZ, and PONVORY, amounted to $102.6 million for the first six months of 2025, representing a 5% increase from the previous year, driven primarily by a 27% year-over-year growth in Fanapt revenue following its bipolar I indication launch. The call highlighted an expansion of the Fanapt sales force to approximately 300 representatives, which resulted in a more than 40% increase in sales activity from Q1 2025 and over 400% from Q2 2024. The net loss for H1 2025 was $56.7 million, reflecting increased operational expenses, including those related to sales force expansion and R&D investments. Vanda reiterated its 2025 financial guidance, projecting total revenues between $210 million and $250 million and year-end cash between $280 million and $320 million. Market exclusivity and potential growth for their pipeline products, such as Bysanti and tradipitant, were also discussed, with upcoming PDUFA dates and ongoing clinical trials indicating potential market entries in 2026.

Fanapt Revenue Growth

Fanapt revenue increased by 27% compared to the same period in the prior year, driven by the launch of the bipolar I indication.

Expansion of Sales Force

The dedicated sales force for Fanapt expanded to approximately 300 representatives, leading to a significant increase in activity with the total number of calls growing by more than 40% compared to the first quarter of 2025.

Bysanti FDA Filing

The NDA for Bysanti for the acute treatment of bipolar I disorder and schizophrenia was accepted by the FDA with a PDUFA target action date of February 21, 2026.

Strong Cash Position

Vanda's cash, cash equivalents, and marketable securities were $325.6 million as of June 30, 2025.

Vanda (VNDA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VNDA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.43 / -	-0.09	―	―	―
Jul 31, 2025	2025 (Q2)	-0.36 / -0.46	-0.08	-475.00% (-0.38)	―
May 07, 2025	2025 (Q1)	-0.57 / -0.50	-0.07	-614.29% (-0.43)	―
Feb 13, 2025	2024 (Q4)	-0.11 / -0.08	-0.04	-100.00% (-0.04)	―
Nov 06, 2024	2024 (Q3)	-0.16 / -0.09	0	―	―
Jul 31, 2024	2024 (Q2)	-0.19 / -0.08	0.03	-366.67% (-0.11)	―
May 08, 2024	2024 (Q1)	0.05 / -0.07	0.06	-216.67% (-0.13)	―
Feb 07, 2024	2023 (Q4)	-0.09 / -0.04	0.12	-133.33% (-0.16)	―
Nov 08, 2023	2023 (Q3)	-0.04 / 0.00	0.06	―	―
Jul 27, 2023	2023 (Q2)	-0.13 / 0.03	0.05	-40.00% (-0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VNDA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$4.67	$4.26	-8.78%
May 07, 2025	$4.38	$4.22	-3.65%
Feb 13, 2025	$4.70	$4.42	-5.96%
Nov 06, 2024	$4.89	$5.02	+2.66%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Vanda Pharmaceuticals Inc. (VNDA) report earnings?

Vanda Pharmaceuticals Inc. (VNDA) is schdueled to report earning on Oct 29, 2025, After Close (Confirmed).

What is Vanda Pharmaceuticals Inc. (VNDA) earnings time?

Vanda Pharmaceuticals Inc. (VNDA) earnings time is at Oct 29, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VNDA EPS forecast?

VNDA EPS forecast for the fiscal quarter 2025 (Q3) is -0.43.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing